Awarded Grants

Ulka Vaishampayan, MBBS: $7,038,011 from Roche Molecular Systems, Inc. for "Biology of Cancer Case-Control Study.” [Translational and Clinical Research]

Isabelle Lombaert, Ph.D.: $2,034,240 from NIH for “Defining the Targets and Function of Direct Trigeminal Sensory Innervation to Salivary Glands.” [Signaling and Tumor Microenvironment]

Clifford Cho, M.D.: $1,378,610 from NIH for “Harnessing the therapeutic potential of histotripsy focused ultrasound-induced immunogenic cancer cell death.” [Cancer Hematopoiesis and Immunology]

Laura Buttitta, Ph.D.: $1,125,000 from NIH for “Probing the flexibility of G0.” [Signaling and Tumor Microenvironment]

Amanda Garner, Ph.D.: $900,000 from Ono Pharma Foundation for “Chemical Manipulation of RNA-Protein Interactions for RNA-Targeted Drug Discovery.” [Developmental Therapeutics]

Debbie Chen, M.D.: $844,705 from NIH for “A Paradigm to Examine Cancer Disparities: Limited English Proficient Chinese Patients with Thyroid Nodules.” [Cancer Control and Population Sciences]

Gary Luker, M.D.: $420,749 from NIH for “Integrated Imaging Tools for Intercellular Chemokine Signaling.” [Translational and Clinical Research]

Chad Brenner, Ph.D.: $389,344 from Department of Defense for “A New Idea for Advancing Axitinib-based Therapy in Recurrent and Metastatic HNSCC.” [Translational and Clinical Research]

Nouri Neamati, Ph.D.: $375,000 from The Children’s Hospital of Philadelphia for “Development and Clinical Translation of MYC Inhibitors for Osteosarcoma.” [Developmental Therapeutics]

Ryan Wilcox, M.D., Ph.D.: $350,000 from Department of Defense for “Targeting T-Cell Lymphomas with a Novel Lectin.” [Cancer Hematopoiesis and Immunology]

Maureen Sartor, Ph.D.: $220,462 from NIH for “Improving chemical exposome target prediction by application of Coupled Matrix/Tensor-Matrix/Tensor Completion algorithms.” [Cancer Genetics]

Sofia Merajver, M.D., Ph.D.: $187,500 from The Breast Cancer Research Foundation for “Targeting RhoC in Breast Cancer: Novel Drugs, Mathematical Models and Epidemiological Studies in North Africa.” [Translational and Clinical Research]

Lynn Henry, M.D., Ph.D.: $187,500 from The Breast Cancer Research Foundation for “Identifying predictors of endocrine therapy toxicity and effective management strategies to improve quality of life for patients with breast cancer.” [Cancer Control and Population Sciences]

Max Wicha, M.D.: $187,500 from The Breast Cancer Research Foundation for “Molecular analysis of breast cancer stem cells at single cell resolution.” [Signaling and Tumor Microenvironment]

Lori Pierce, M.D.: $187,500 from The Breast Cancer Research Foundation for “Breast Cancer Cell Sensitivity To Radiotherapy In The Presence Of Targeted Therapies.” [Translational and Clinical Research]

Sean Hannifin, M.S. (mentored by Kyoung Lee, Ph.D.): $163,256 from NIH for “Hypoxic regulation of macrophage migration and function via fibroblast reprogramming in pancreatic cancer.” [Signaling and Tumor Microenvironment]

Terrance Haanen, B.S. (mentored by Goutham Narla, M.D., Ph.D.): $122,442 from NIH for “Deciphering the functional role of recurrent PPP2R1A mutations on endometrial metastasis.” [Cancer Genetics]

Susan Pitt, M.D.: $107,722 from NIH for “A Pilot Feasibility Study of an Intervention to Decrease Overtreatment of Low-risk Thyroid Cancer.” [Cancer Control and Population Sciences]

Erin Cobain, M.D.: $106,660 from Epic Sciences for “Monitoring treatment response in Metastatic breast cancer with novel liquid biopsy Methodology.” [Translational and Clinical Research]

Zhen Xu, Ph.D.: $100,000 from Focused Ultrasound Foundation for “Investigate the impact of histotripsy dosing on liver cancer therapeutic outcomes (local and abscopal tumor response, development of metastases, and survival).” [Developmental Therapeutics]

James Haggerty-Skeans, B.S. (mentored by Sriram Venneti, M.D., Ph.D.): $80,768 from NIH for “The role of PTEN in epigenetic and metabolic regulation of IDH-mutant gliomas.” [Cancer Genetics]